Literature DB >> 20497005

Effects of STAT3 silencing on fate of chronic myelogenous leukemia K562 cells.

Ling-di Ma1, Min Zhou, Shi-hong Wen, Cheng Ni, Li-jia Jiang, Jing Fan, Lei Xia.   

Abstract

Signal transducer and activator of transcription 3 (STAT3), a transcription factor, is constitutively activated in various types of cancers. Previous investigations have demonstrated that this overexpression of STAT3 in human malignancies plays important roles in maintaining the characteristics of malignant tumors by having an effect on proliferation, differentiation, and/or immortalization. Thus, inhibition of STAT3 expression could be a potent therapeutic approach in cancer treatment. In this study, we introduced STAT3 siRNA into the human chronic myelogenous leukemia (CML) K562 cell line, which has constitutive activation of STAT3, to elucidate the role of STAT3 in CML. The cells were transducted with STAT3 siRNA using lentivirus. FACS, real-time PCR, and Western blot were used to study changes in STAT3 expression levels in transducted cells by comparing with negative control siRNA lentivirus transduction. Knockdown of STAT3 by STAT3 siRNA caused a decrease in STAT3 protein level, inhibition of growth and proliferation, cell cycle blockade, visible morphologic changes, and induction of apoptosis in K562 cells. These findings demonstrate that STAT3 does indeed play a critical role in the survival of K562 cells, which may have potential application in designing molecular therapies for CML treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20497005     DOI: 10.3109/10428194.2010.483748

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

1.  Effects of lentivirus mediated STAT3 silencing on human chronic myeloid leukemia cells and leukemia mice.

Authors:  Xinyan Jia; Wenzhong Yang; Jia Han; Hong Xiong
Journal:  Int J Clin Exp Med       Date:  2014-11-15

2.  Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor.

Authors:  Michele S Redell; Marcos J Ruiz; Todd A Alonzo; Robert B Gerbing; David J Tweardy
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

3.  Investigating the potential therapeutic role of targeting STAT3 for overcoming drug resistance by regulating energy metabolism in chronic myeloid leukemia cells.

Authors:  Burcin Tezcanli Kaymaz; Nur Selvi Gunel; Fatma Sogutlu; Neslihan Pinar Ozates Ay; Yusuf Baran; Cumhur Gunduz; Cigir Biray Avci
Journal:  Iran J Basic Med Sci       Date:  2022-07       Impact factor: 2.532

4.  Role of STAT3 in Transformation and Drug Resistance in CML.

Authors:  Rajesh R Nair; Joel H Tolentino; Lori A Hazlehurst
Journal:  Front Oncol       Date:  2012-04-10       Impact factor: 6.244

5.  Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.

Authors:  André L Mencalha; Stephany Corrêa; Daniela Salles; Bárbara Du Rocher; Marcelo F Santiago; Eliana Abdelhay
Journal:  BMC Cancer       Date:  2014-11-23       Impact factor: 4.430

6.  Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells.

Authors:  Ofer Regev; Noa Kidan; Meshel Nicola; Hazem Khamisie; Martin Ruthardt; Jamal Mahajna
Journal:  Arch Med Sci       Date:  2020-11-20       Impact factor: 3.318

7.  New insights into the Shwachman-Diamond Syndrome-related haematological disorder: hyper-activation of mTOR and STAT3 in leukocytes.

Authors:  Valentino Bezzerri; Antonio Vella; Elisa Calcaterra; Alessia Finotti; Jessica Gasparello; Roberto Gambari; Baroukh Maurice Assael; Marco Cipolli; Claudio Sorio
Journal:  Sci Rep       Date:  2016-09-23       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.